ClinicalTrials.gg
Enrolling by invitationNCT07917806Updated Nov 5, 2026

A RCT of Collagen Scaffold for the Repair of Talus Cartilage Injury

A Phase 3 interventional study of Collagen Scaffold (Colla-Plug) and microfracture in Cartilage Defects and Talus Osteochondral Defect, sponsored by Beijing Jishuitan Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beijing Jishuitan Hospital · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to test whether adding a collagen protein scaffold can improve cartilage repair of talus injury, compared to standard surgery alone. The study will enroll 40 patients (aged 18-55) with talus cartilage damage who haven't responded to conservative treatments.

The main questions it aims to answer are:

  • Does the collagen scaffold help regenerate better-quality cartilage (measured by MRI scans at 3/6 months and 1/2 years)?
  • Do patients experience better pain relief and ankle function after this combined treatment?

Researchers will compare two groups:

  • Experimental group: Receives microfracture surgery + collagen scaffold implant
  • Active Comparator group: Receives microfracture surgery alone

Participants will:

  • Undergo arthroscopic surgery (either procedure)
  • Complete follow-up visits at 1 week, 1 month, 3 months, 6 months, 1 year and 2 years
  • Have MRI scans and functional assessments
  • Report pain levels and daily activity limitations through questionnaires
02

Conditions studied

  • Cartilage Defects
  • Talus Osteochondral Defect

Keywords

  • cartilage scaffold
03

In context

Lead sponsor

Beijing Jishuitan Hospital is the lead sponsor of 44 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects are between the ages of 18 and 55 (including 18 and 55 years old);
  2. Articular cartilage defect reaches Outerbridge grade III/IV;
  3. The area of cartilage defect in a single site is 1cm²-3cm²;
  4. 18≤BMI≤30;
  5. Clinically diagnosed cartilage defect requiring arthroscopic microfracture;
  6. Have not participated in other clinical trials within 3 months;
  7. Conservative treatment for more than 3 months has not been effective
  8. Subjects fully understand the benefits and risks of this trial, are willing to participate and sign the form, and are able to cooperate with clinical follow-up

Exclusion criteria

Exclusion Criteria:

  1. Subjects with significant narrowing of the ankle joint space or bony ankylosis (bone bridge formation).
  2. Subjects with severe subchondral bone damage unsuitable for microfracture surgery.
  3. Subjects with severe ankle deformity or systemic bone/joint diseases.
  4. Subjects with allergic predisposition (e.g., porcine protein allergy) or personal/family history of diseases.
  5. Subjects who received autologous bone marrow mesenchymal stem cell transplantation or other cartilage regeneration surgery for cartilage defects in the affected ankle within 12 months prior to surgery.
  6. Subjects whose ankle cartilage injury was caused by articular fractures, infections, tumors, or immune-mediated diseases.
  7. Subjects with ankle tumors, rheumatoid arthritis, tuberculosis, suppurative arthritis, or complications affecting joint structure.
  8. Subjects with secondary ankle arthritis accompanied by psoriasis, syphilitic neuropathy, ochronosis, or metabolic bone diseases.
  9. Subjects with frequent use of sedatives, hypnotics, tranquilizers, or other addictive drugs.
  10. Subjects with severe primary cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic system diseases, or psychiatric disorders.
  11. Subjects unable to comply with long-term intensive postoperative rehabilitation.
  12. Female subjects planning pregnancy within 12 months, or currently pregnant or lactating.
  13. Subjects with specific religious beliefs prohibiting porcine-derived products.
  14. Other subjects deemed ineligible by investigators (e.g., inability to evaluate treatment efficacy).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Microfracture + Collagen scaffold

    Device: Collagen Scaffold (Colla-Plug) · Procedure: microfracture

  • Active comparator
    Microfracture

    Procedure: microfracture

Interventions

  • DeviceCollagen Scaffold (Colla-Plug)

    The collagen cartilage scaffold(COLTRIX® CartiRegen) used in this study consist of an injection needle, a syringe, and a collagen gel prefilled in a syringe. The collagen gel contains phosphate buffer and type I collagen which the telopeptides are removed.. After the product is implanted in the body, it forms a degradable three-dimensional scaffold to provide an environment for cells to adhere, proliferate, migrate, differentiate and secrete, thereby promoting cartilage repair. At present, it has been commercially applied to clinical repair of knee cartilage defect.

  • Proceduremicrofracture

    Microfracture to repair cartilage defect is a minimally invasive procedure that is usually done arthroscopically. The doctor first cleans the damaged cartilage area, and then uses a special microfracture cone to drill vertically in the subchondral bone plate, forming multiple tiny holes, allowing mesenchymal stem cells and growth factors in the bone marrow to overflow, forming a blood clot rich in repair components, and finally stimulating fibrocartilage regeneration to fill the defect area.

06

What researchers measure

Primary outcomes

  1. MOCART score

    The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scoring system includes multiple dimensions such as the morphology of the repaired tissue, the thickness of the repaired cartilage, the signal intensity of the repaired tissue, the integration of the repaired cartilage with normal cartilage, the bone quality under the repaired cartilage, the accumulation or inflammation of the joint cavity, and the coverage of cartilage defects. Morphology and its integration with the surrounding normal cartilage.

    Time frame: Preoperatively, 3rd and 6th months and 1st and 2nd postoperatively

Secondary outcomes

  1. Range of motion

    The range of motion (ROM), measured in degrees (°) using the neutral-zero method, includes: sagittal plane dorsiflexion (0°-20°) and plantarflexion (0°-50°) at the talocrural joint, and frontal plane/horizontal plane inversion (0°-35°) and eversion (0°-15° to 20°) at the subtalar joint. Anatomically, the neutral reference position is 90° between the foot and leg, with the goniometer axis placed inferior to the lateral malleolus or midpoint of the bimalleolar line, the stationary arm aligned with the fibular/leg axis, and the moving arm aligned with the 5th metatarsal or calcaneus axis. Active and passive ROM should be documented separately, with unilateral findings compared to the contralateral side to assess restriction.

    Time frame: Preoperatively, 1st week, 1st month, 3rd month, 6th month,1st year and 2nd year postoperatively.

  2. Visual Analogue Scale(VAS)

    A Visual Analogue Scale (VAS) is a straight-line measurement tool where respondents mark their perceived intensity of a symptom-such as pain-along a continuous 0-100 mm continuum.

    Time frame: Preoperatively, 1st week, 1st month, 3rd month, 6th month,1st year and 2nd year postoperatively.

  3. Kellgren-Lawrence Grade

    The Kellgren-Lawrence (KL) grade is a standardized radiological scoring system (grades 0-4) used to classify the severity of osteoarthritis based on features such as joint space narrowing, osteophytes, and subchondral sclerosis.

    Time frame: Preoperatively, 1st week, 1st month, 3rd month, 6th month,1st year and 2nd year postoperatively.

  4. Tegner score

    The Tegner score is a clinician-reported scale (0-10) that rates a patient's activity level by linking knee function to the demands of specific sports and occupational activities.

    Time frame: Preoperatively, 1st week, 1st month, 3rd month, 6th month,1st year and 2nd year postoperatively.

  5. American Orthopedic Foot and Ankle Society Score (AOFAS)

    The AOFAS score is a clinician-based 100-point ankle-foot rating system that evaluates pain, function, and alignment to assess outcomes in foot and ankle disorders.

    Time frame: Preoperatively, 1st week, 1st month, 3rd month, 6th month,1st year and 2nd year postoperatively.

07

Study locations

1 site
08

References and documents

Publications

  • Kim SJ, Shetty AA, Kurian NM, Ahmed S, Shetty N, Stelzeneder D, Shin YW, Cho YJ, Lee SH. Articular cartilage repair using autologous collagen-induced chondrogenesis (ACIC): a pragmatic and cost-effective enhancement of a traditional technique. Knee Surg Sports Traumatol Arthrosc. 2020 Aug;28(8):2598-2603. doi: 10.1007/s00167-020-05884-y. Epub 2020 Feb 17. PubMed 32064573 ↗
  • Shetty AA, Kim SJ, Shetty V, Jang JD, Huh SW, Lee DH. Autologous collagen induced chondrogenesis (ACIC: Shetty-Kim technique) - A matrix based acellular single stage arthroscopic cartilage repair technique. J Clin Orthop Trauma. 2016 Jul-Sep;7(3):164-9. doi: 10.1016/j.jcot.2016.05.003. Epub 2016 Jun 14. PubMed 27489411 ↗
  • Shetty AA, Kim SJ, Bilagi P, Stelzeneder D. Autologous collagen-induced chondrogenesis: single-stage arthroscopic cartilage repair technique. Orthopedics. 2013 May;36(5):e648-52. doi: 10.3928/01477447-20130426-30. PubMed 23672920 ↗

Individual participant data

Plan to share: Yes — This study will share the medical history and physical examination, imaging data (X-ray, CT, MRI, etc.) , functional scores, laboratory test results and complications of the two groups of patients with talus cartilage defect.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Aug 2028, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Nov 5, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07917806
Lead sponsor
Beijing Jishuitan Hospital
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
Oct 1, 2026
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion